metoclopramide, Reglan, Reglan ODT, Metozol ODT, Octamide, (Maxolon discontinued)
Omudhome Ogbru, PharmD
Omudhome Ogbru, PharmD
Dr. Ogbru received his Doctorate in Pharmacy from the University of the Pacific School of Pharmacy in 1995. He completed a Pharmacy Practice Residency at the University of Arizona/University Medical Center in 1996. He was a Professor of Pharmacy Practice and a Regional Clerkship Coordinator for the University of the Pacific School of Pharmacy from 1996-99.
Medical and Pharmacy Editor:
GENERIC NAME: metoclopramide
BRAND NAME: metoclopramide, Reglan, Reglan ODT, Metozol ODT, Octamide, (Maxolon discontinued)
DRUG CLASS AND MECHANISM: Metoclopramide is a "prokinetic" drug that stimulates the muscles of the gastrointestinal tract including the muscles of the lower esophageal sphincter, stomach, and small intestine by interacting with receptors for acetylcholine and dopamine on gastrointestinal muscles and nerves.
The lower esophageal sphincter, located between the esophagus and the stomach, normally prevents reflux of acid and other contents in the stomach from backing up into the esophagus. In patients with gastroesophageal reflux disease (GERD), a weakened lower esophageal sphincter allows reflux of stomach acid into the esophagus, causing heartburn and damage to the esophagus (esophagitis). Metoclopramide decreases the reflux of stomach acid by strengthening the muscle of the lower esophageal sphincter. Metoclopramide also stimulates the muscles of the stomach and thereby hastens emptying of solid and liquid meals from the stomach and into the intestines.
In some patients, particularly those with diabetes, damage to nerves in the stomach can interfere with function of the muscles and cause delayed emptying of the stomach, resulting in nausea, vomiting, a sense of abdominal fullness and distention, and heartburn (diabetic gastroparesis). Metoclopramide can be effective in relieving the symptoms related to diabetic gastroparesis by stimulating more rapid emptying of the stomach as well as decreasing the reflux of stomach acid into the esophagus. Dopamine receptors on nerves in the brain are important in producing nausea. Metoclopramide interacts with the dopamine receptors in the brain and can be effective in treating nausea. The FDA approved metoclopramide in June 1985.
GENERIC AVAILABLE: Yes
STORAGE: Tablets and syrup should be stored between 15-30 C (59-86 F). Injectable metoclopramide should be stored at room temperature 20-25 C (68-77 F).
PRESCRIBED FOR: Metoclopramide is used on a short term basis (4 to 12 weeks) for treating patients with heartburn and esophagitis due to GERD and for treating patients who have gastroparesis. Metoclopramide is used to promote emptying of the stomach prior to radiological examinations and to facilitate passage of tubes passed through the nose or mouth and into the small intestine. It is used for treating impaired function of muscles of the small intestine that may give rise to symptoms that mimic intestinal obstruction (nausea, vomiting, and abdominal distention). Metoclopramide also is used in the treatment of nausea due to surgery or cancer chemotherapy.
The usual dose of metoclopramide for treating GERD is 10-15 mg four times daily, 30 minutes before each meal.
Gastroparesis is treated with 10 mg administered orally four times daily, 30 minutes before each meal and at bedtime.
DRUG INTERACTIONS: Since metoclopramide accelerates emptying of the stomach, it can increase or decrease absorption and effects of other drugs that are absorbed in the small intestine. For example, the effects of alcohol, diazepam (Valium) and cyclosporine can be accelerated when used together with metoclopramide. Conversely, metoclopramide may decrease the concentrations in blood of digoxin (Lanoxin) and cimetidine (Tagamet). Metoclopramide should not be used in patients taking MAO inhibitors for example, isocarboxazid (Marplan), phenelzine (Nardil), tranylcypromine (Parnate), selegiline (Eldepryl), and procarbazine (Matulane), because of the risk of serious adverse effects due to excess release of neurotransmitters. Concurrent administration of anticholinergic drugs can decrease the effectiveness of metoclopramide.
Report Problems to the Food and Drug Administration
You are encouraged to report negative side effects of prescription drugs to the FDA. Visit the FDA MedWatch website or call 1-800-FDA-1088.
Need help identifying pills and medications?
Back to Medications Index